Aclaris Therapeutics ACRS Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Aclaris Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OtherLiabilitiesCurrent.
The official record: Aclaris Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Aclaris Therapeutics's accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Aclaris Therapeutics's accrued expenses?
- Aclaris Therapeutics (ACRS) reported accrued expenses of $2.77M in Q1 2026.
- How has Aclaris Therapeutics's accrued expenses changed year-over-year?
- Aclaris Therapeutics's accrued expenses increased by 2.6% year-over-year, from $2.7M to $2.77M.
- What is the long-term trend for Aclaris Therapeutics's accrued expenses?
- Over 5 years (2020 to 2025), Aclaris Therapeutics's accrued expenses has grown at a 35.5% compound annual growth rate (CAGR), from $603K to $2.75M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.